Open Orphan seals deal that could net more than €11.6m
Dublin-listed pharma group announces contract with European biotech company
Open Orphan executive chairman Cathal Friel said the acquisition of Hvivo was reaping benefits for the company. Photograph: Alan Betson / The Irish Times
Dublin-listed pharma services company Open Orphan has announced the signing of a new contract with a European biotech company that could yield it more than £10 million in revenue this year.
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed the Irish stock exchange of the deal for the provision of an respiratory syncytial virus (RSV) human challenge study on Friday.